

19<sup>th</sup> January, 2015

Alltherm Sa  
Via Gerretta 6a  
6500 Bellinzona  
Switzerland

**Subject: Synacthen (i.m., i.v.) Injektionslosung - 31723,  
Synacthen Depot 1 mg/ml. Injektionssuspension - 33801:**

**Important changes.**

Dear Customer,

Questcor Operations Ltd is a wholly owned subsidiary of Mallinckrodt Pharmaceuticals plc, a leading specialty biopharmaceutical company that recently acquired the rights for Synacthen and Synacthen Depot from Novartis AG.

The objective of this letter is to inform you of the need to increase the price of Synacthen & Synacthen Depot (a synthetic ACTH analogue) to ensure the long-term supply of the product for patients in Switzerland.

Synacthen & Synacthen Depot were launched in Switzerland in the mid-1960's and are still playing a very important and unique role in today's treatment of multiple, serious and difficult to treat diseases such as cancer, Crohn's Disease, rheumatism and Multiple Sclerosis. Since the 1960's, six of the seven ACTH brands in Europe have been discontinued, leaving Synacthen Depot as the only therapeutic ACTH available in Europe.

In the short term, we have taken steps to substantially improve the supply of Synacthen and Synacthen Depot. To address the issue of long-term supply, we need to take immediate action to ensure the products will not be forced from the market. The long-term supply concern arises from notice given by the current sole worldwide manufacturer of Synacthen & Synacthen Depot, of its inability to supply the product beyond April 2016 due to a planned manufacturing site decommission.

This means, without immediate significant actions and investments from us to secure future manufacturing, the supply of this important product to all approved markets will cease later in 2016, leaving Switzerland and other countries with no ACTH alternative for seriously ill patients.


The current price of Synacthen (i.m., i.v.) Injektionslösung and Synacthen Depot 1 mg/ml. Injektionssuspension, does not allow for the necessary investments to assure long-term product availability to patients in Switzerland.

As such, the following table reflects the new pricing (the wholesale price) in order to move forward with these initiatives:

<b>Product</b>	<b>Swissmedic-Nr.</b>	<b>Pharma-Code</b>	<b>Price for the wholesalers (CHF) from Jan 15<sup>th</sup> 2015</b>
Synacthen (0.25 mg), 10 Ampullen	31723	97755	600.00
Synacthen Depot (1mg), 10 Ampullen	33801	97778	600.00

The above pricing is effective on 15<sup>th</sup> January, 2015.

Yours faithfully,



Ruud Helwig  
General Manager, International  
**Mallinckrodt ARD**

Marco Montagnolo  
Country Manager European Markets  
**Mallinckrodt Schweiz AG**